Intra-Cellular Therapies (ITCI) Competitors

$73.26
+1.13 (+1.57%)
(As of 04/26/2024 ET)

ITCI vs. VKTX, JAZZ, CYTK, CERE, ELAN, IONS, ASND, APLS, LEGN, and BPMC

Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.

Intra-Cellular Therapies vs.

Viking Therapeutics (NASDAQ:VKTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.

Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -30.08%. Viking Therapeutics' return on equity of -23.02% beat Intra-Cellular Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -25.49% -24.41%
Intra-Cellular Therapies -30.08%-23.02%-19.39%

In the previous week, Viking Therapeutics had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 26 mentions for Viking Therapeutics and 21 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.76 beat Viking Therapeutics' score of 0.57 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
12 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intra-Cellular Therapies
5 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viking Therapeutics currently has a consensus target price of $112.25, indicating a potential upside of 51.06%. Intra-Cellular Therapies has a consensus target price of $90.17, indicating a potential upside of 23.08%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, research analysts plainly believe Viking Therapeutics is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00
Intra-Cellular Therapies
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Viking Therapeutics received 94 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 67.34% of users gave Intra-Cellular Therapies an outperform vote.

CompanyUnderperformOutperform
Viking TherapeuticsOutperform Votes
597
79.92%
Underperform Votes
150
20.08%
Intra-Cellular TherapiesOutperform Votes
503
67.34%
Underperform Votes
244
32.66%

Viking Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Viking Therapeutics has higher earnings, but lower revenue than Intra-Cellular Therapies. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$85.89M-$0.93-79.90
Intra-Cellular Therapies$464.37M15.27-$139.67M-$1.46-50.18

Summary

Viking Therapeutics beats Intra-Cellular Therapies on 12 of the 17 factors compared between the two stocks.

Get Intra-Cellular Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ITCI vs. The Competition

MetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.98B$6.54B$4.90B$7.45B
Dividend YieldN/A3.09%2.92%3.95%
P/E Ratio-50.189.18154.7114.85
Price / Sales15.27300.432,358.6484.60
Price / CashN/A28.9146.5534.73
Price / Book11.915.944.774.33
Net Income-$139.67M$141.82M$103.52M$214.13M
7 Day Performance1.23%0.65%0.78%1.87%
1 Month Performance5.08%-10.55%-7.51%-5.24%
1 Year Performance18.41%-2.24%9.15%8.38%

Intra-Cellular Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VKTX
Viking Therapeutics
4.5503 of 5 stars
$64.93
+1.7%
$112.25
+72.9%
+280.1%$7.16BN/A-70.5827Earnings Report
Analyst Report
Analyst Revision
JAZZ
Jazz Pharmaceuticals
4.8498 of 5 stars
$109.67
+0.8%
$195.08
+77.9%
-20.6%$6.91B$3.83B17.922,800Upcoming Earnings
CYTK
Cytokinetics
3.6304 of 5 stars
$65.57
-1.1%
$79.33
+21.0%
+75.9%$6.86B$7.53M-12.03423Insider Selling
Short Interest ↑
News Coverage
CERE
Cerevel Therapeutics
0.3296 of 5 stars
$41.99
-0.3%
$41.40
-1.4%
+51.3%$7.62BN/A-16.80334Upcoming Earnings
Short Interest ↓
ELAN
Elanco Animal Health
3.8685 of 5 stars
$13.45
+4.0%
$16.71
+24.3%
+43.2%$6.63B$4.42B-5.389,300Short Interest ↑
IONS
Ionis Pharmaceuticals
4.0815 of 5 stars
$41.84
+1.9%
$56.08
+34.0%
+16.3%$6.10B$788M-16.34927Upcoming Earnings
ASND
Ascendis Pharma A/S
2.3383 of 5 stars
$144.83
+1.9%
$173.25
+19.6%
+77.8%$8.43B$288.08M-15.66879Short Interest ↑
News Coverage
APLS
Apellis Pharmaceuticals
4.5054 of 5 stars
$48.72
+2.3%
$77.93
+60.0%
-41.1%$5.87B$396.59M-10.87702Analyst Report
Analyst Revision
News Coverage
Gap Up
LEGN
Legend Biotech
2.1608 of 5 stars
$47.45
+0.8%
$83.26
+75.5%
-33.3%$8.63B$285.14M-32.061,800Analyst Report
BPMC
Blueprint Medicines
0.7367 of 5 stars
$92.29
+1.9%
$85.43
-7.4%
+89.7%$5.65B$249.38M-11.04655Upcoming Earnings
Analyst Report
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:ITCI) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners